Last reviewed · How we verify
Caroxime sodium sulfonate
Caroxime sodium sulfonate is an oxime compound that acts as an acetylcholinesterase reactivator, restoring cholinergic neurotransmission by removing phosphoryl groups from inhibited enzyme active sites.
Caroxime sodium sulfonate is an oxime compound that acts as an acetylcholinesterase reactivator, restoring cholinergic neurotransmission by removing phosphoryl groups from inhibited enzyme active sites. Used for Organophosphate pesticide poisoning, Organophosphate nerve agent exposure.
At a glance
| Generic name | Caroxime sodium sulfonate |
|---|---|
| Sponsor | Chengdu University of Traditional Chinese Medicine |
| Drug class | Acetylcholinesterase reactivator (oxime) |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Toxicology / Antidote |
| Phase | FDA-approved |
Mechanism of action
This drug belongs to the class of oxime-based cholinesterase reactivators used primarily in organophosphate poisoning. It penetrates the blood-brain barrier and reactivates acetylcholinesterase that has been inhibited by organophosphate compounds (pesticides, nerve agents), thereby restoring normal neuromuscular and autonomic function. The mechanism is particularly relevant for acute poisoning scenarios where rapid restoration of enzyme activity is critical.
Approved indications
- Organophosphate pesticide poisoning
- Organophosphate nerve agent exposure
Common side effects
- Dizziness
- Nausea
- Headache
- Blurred vision
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: